Marker Therapeutics shares rise 2.06% after-hours following positive clinical data presentation at EASD.

Marker Therapeutics, Inc. rose 2.06% in after-hours trading, with the company presenting a new retrospective analysis at the European Association for the Study of Diabetes (EASD) Annual Meeting. The analysis supports the potential of Diamyd® (rhGAD65/alum), a precision medicine immunotherapy, in preserving insulin production in individuals with Stage 3 Type 1 Diabetes.